Insights

Washington – June 4, 2026: Crowell & Moring earned 92 individual rankings for 81 attorneys, as well as 48 national and statewide practice area rankings, in the Chambers USA 2026 guide. The Chambers guide ranks the country’s top law firms and lawyers through in-depth research, client interviews, and feedback from attorneys at peer firms. 

Irvine, Calif. – January 27, 2026: John Paik, an intellectual property attorney with more than two decades of experience at leading law firms and technology companies, has joined Crowell & Moring as a partner in the firm’s Intellectual Property Department in Orange County.

London – October 16, 2025: Chambers and Partners has ranked Crowell & Moring U.K. LLP and its lawyers across the United Kingdom as leaders in their respective practice areas in the Chambers UK 2026 Guide.

For 15 years, the question “Should we file an IPR?” was easy. The answer — almost invariably — was “yes.” High institution rates, a famously skeptical U.S. Patent Trial and Appeal Board (PTAB), and minimal downside made inter partes review (IPR) a nearly reflexive tool in the litigator’s arsenal. U.S. Patent and Trademark Office (USPTO) Director Squires’ precedential decision issued May 14, 2026, in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (IPR2026-00097) provides clarity to that calculus.

On April 30, 2026, USPTO Director John A. Squires issued an updated memorandum superseding the December 4, 2025, guidance on Best Practices for Submission of Rule 132 Subject Matter Eligibility Declarations (SMEDs). The USPTO has also created a new position — Deputy Commissioner for Patents focusing on AI Policy, Practice, and Operations — and has welcomed longtime practitioner and private-sector AI expert Barry Schindler to this role. This alert summarizes the key updates and actionable guidance for patent applicants and practitioners.

As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?

The Patent Prosecution Highway (PPH) program is a collaborative initiative between the United States Patent and Trademark Office (USPTO) and several foreign patent offices, created to speed up the examination process. Through the PPH, a patent application initially filed with a participating patent office (Office of Earlier Examination, or OEE) can be expedited in another participating intellectual property office, provided it meets specific requirements. According to the USPTO, PPH leverages fast-track examination procedures already in place among participating patent offices to allow applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing.